SEC Filing Summary: Form 6-K
Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of May 2023, specifically dated May 2, 2023. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The filing serves to incorporate a press release (Exhibit 99.1) by reference into the company's Registration Statements on Form S-8.
Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or earnings report.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this specific filing text. The document solely references the issuance of a press release on May 2, 2023.
Guidance, Outlook, and Risks
The filing incorporates a press release by reference but does not summarize its content within the Form 6-K text itself. Consequently, specific guidance, management commentary, risks, contingencies, or unusual items are not detailed in this excerpt. The text notes that quotes from Dr. Paul Stoffels and Bart Filius in the attached press release are excluded from incorporation by reference.
Key Facts for Investor Verification
- Entity Discrepancy: The metadata lists "Lakefront Biotherapeutics NV," but the filing is explicitly for "Galapagos NV." Investors must verify the correct issuer.
- Content Source: All substantive information regarding the May 2, 2023 event is contained in the attached Exhibit 99.1 (Press Release), which is not included in the provided text.
- Regulatory Status: The company files annual reports on Form 20-F.
- Exclusions: Specific quotes from Dr. Paul Stoffels and Bart Filius in the press release are not incorporated by reference into the S-8 registration statements.